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Figure S1. Effects of gain and loss of EGFR signaling on sleep architecture 
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Fig. S1. Effects of gain and loss of EGFR signaling on sleep architecture. (A) ISH using an 
egf-specific riboprobe in a 6-dpf zebrafish brain. Scale: 50 m. (B,C) qPCR analysis of tgfa (B) 
and per1b (C) expression in 14:10 h light:dark conditions, each normalized to ef1a, over 36 hours 
beginning at 5-dpf. RNA from twenty pooled animals was assayed at each time point. Pooled data 
from 3 independent biological replicates shows a significant difference between peak and trough 
transcript level for tgfa and per1b (*p<0.05, ***p<0.005, One-way ANOVA, Holm-Sidak test). 
a.u.= arbitrary units. (D-H) In Tg(hs:tgfa) animals, heat shock-induced TGFa overexpression 
increased daytime sleep bout number (D) and daytime and nighttime sleep bout length (E) 
compared to WT siblings. TGFa overexpression also decreased daytime wake bout length (F) and 
sleep latency (time to first sleep bout) (G), as well as daytime and nighttime waking activity (H) 
compared to WT siblings. (I-AJ) Genetic loss of EGFR signaling components increased 
locomotor activity and decreased sleep compared to sibling controls. (I-Q) tgfa -/- animals were 
more active during the day and night, and slept less during the day, than tgfa +/+ siblings. (M-Q) 
tgfa -/- animals had fewer and longer sleep bouts, and higher waking activity, compared to tgfa 
+/+ siblings during the day. (R-Z) egf -/- animals exhibited increased daytime activity and 
waking activity, and showed a trend of less sleep during the day and night, compared to egf +/+ 
siblings. (AA-AE) egf -/-; tgfa -/- animals had fewer sleep bouts, longer wake bouts, longer sleep 
latency, and higher waking activity during the day, and shorter sleep bouts at night, compared to 
egf +/+; tgfa -/- siblings. (AF-AJ) egfra -/- animals have fewer sleep bouts and higher waking 
activity during the day, and shorter sleep bouts and lower waking activity at night, compared to 
egfra +/+ siblings. Mean ± SEM from 2 (D-H), 11 (I-Q), 3 (R-Z), 8 (AA-AE) and 9 (AF-AJ) 
pooled experiments are shown. n=number of animals. *p<0.05, **p<0.01, ***p<0.005 by Two-
way ANOVA with Holm–Sidak test (D-H) or One-way ANOVA with Holm–Sidak test (I-AJ). 
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Figure S2. Amino acid alignment of human and zebrafish TGFa, EGF and EGFR
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Fig. S2. Amino acid alignment of human and zebrafish TGFa, EGF, and EGFR. Alignment 
of the amino acid sequence of human (Hs), WT zebrafish (Dr) and mutant zebrafish (Dr mut) 
TGFa (A), EGF (B) and EGFR (C). Green and black lines above alignments indicate EGF repeat 
domains and transmembrane domains (TMD), respectively. TGFa Dr mut has a 7 bp deletion 
after amino acid 8, resulting in a translational frame shift that generates a predicted protein that 
lacks both of these domains. EGF Dr mut has a 26 bp insertion after amino acid 142, resulting in 
a translational frame shift that generates a predicted protein that lacks 5 EGF domains and the 
TMD. EGFRa Dr mut contains an 11 bp deletion and 27 bp insertion after amino acid 264, 
resulting in a translational frame shift before the TMD and intracellular domains required to 
interact with downstream effectors. Colors indicate amino acids with similar chemical properties. 
Grey shading indicates frame shifted sequence in mutant proteins. 
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Figure S3. Gefitinib does not enhance egfra -/- phenotype and effects 
of EGFR inhibitors on sleep architecture
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Fig. S3. Gefitinib does not enhance egfra
–/–
 phenotype and effects of EGFR inhibitors on 
sleep architecture. (A,B) Gefitinib-treated animals sleep less than DMSO vehicle-treated 
siblings during the day and night, and DMSO-treated egfra -/- animals sleep less than DMSO-
treated egfra +/+ siblings during the day and night, but gefitinib-treated egfra -/- animals do not 
sleep less than DMSO vehicle-treated egfra -/- animals. Thus, gefitinib treatment does not 
enhance the egfra -/- phenotype. Data are from night 5 dpf (B) and day 6 dpf (A) (24 h total). (C-
G) WT animals treated with gefitinib had fewer sleep bouts, longer wake bouts, increased sleep 
latency and increased waking activity during the day, and shorter sleep bouts, increased sleep 
latency and longer wake bouts at night compared to DMSO control-treated siblings. (H-P) WT 
animals treated with erlotinib were more active during the day and night (H,I) and slept less at 
night (K,L) compared to DMSO control-treated siblings. (J,M-P) Erlotinib-treated animals had 
shorter sleep bouts at night, and longer wake bouts, increased sleep latency and increased waking 
activity during the day and night, compared to DMSO-treated siblings. Pooled data from 5 (A-B), 
6 (C-G) and 5 (H-P) experiments are shown. Bar graphs show mean ± SEM. n=number of 
animals. *p<0.05, **p<0.01, ***p<0.005, n.s. p>0.05 by Two-way ANOVA with Dunnett’s test 
(A,B) or Student’s t-test (C-G,I,J,L-P). 
  
 
Fig. S4. EGFR signaling is not required for behavioral circadian rhythms. Locomotor 
activity and sleep behavioral traces of WT animals that were entrained in 14:10 h light:dark 
conditions until 5-dpf, and then shifted to constant light (A,B) or constant dark (C,D) free-running 
conditions. WT animals treated with gefitinib starting on the afternoon of 4-dpf were more active 
and slept less than DMSO-treated siblings, but showed normal circadian regulation of locomotor 
activity and sleep, and apparently normal circadian period length and phase. Pooled data from 6 
(A,B), and 2 (C,D) independent experiments are shown. n=number of animals. Black, white, and 
hatched bars under behavioral traces indicate night (10 h), day (14 h), subjective night (10 h, 
A,B), and subjective day (14 h, C,D) respectively. 
  
Figure S4. EGFR signaling is not required for behavioral circadian rhythms
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Figure S5. Validation of a sleep deprivation assay and EGFR signaling 
is required for normal homeostatic regulation of sleep
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Fig. S5. Validation of an SD assay, and EGFR signaling is required for normal homeostatic 
regulation of sleep. (A) Sleep behavioral traces for WT animals that were sleep deprived during 
the first 6 h of night at 7-dpf (P, orange) followed by a period of recovery sleep during the 
remaining 4 h of night (RS, purple) (red trace), as well as their non-perturbed siblings (blue trace). 
(B-D) Quantification of sleep during the night before the night perturbation (N6: 6-dpf), during 
the 4 h immediately after the night perturbation (RS: last 4 h of night at 7-dpf), and during the 
night after the night perturbation (N8: night of 8-dpf). Night perturbed animals showed 
significantly more sleep than non-perturbed controls only during the SR period (C). (E) Sleep 
behavioral traces for WT animals that were perturbed for 6 h during the middle of the day (ZT2-
ZT8) at 7-dpf (P, orange) followed by a 4 h period of recovery sleep (RS) immediately thereafter, 
during which time they were monitored in the dark (red trace), as well as their non-perturbed 
siblings (blue trace). Animals were maintained in constant dark for the remainder of the 
experiment. (F-H) Quantification of sleep during the night before the day perturbation (N6: 6-
dpf), during the 4 h immediately after the day perturbation (RS: 4 hours of subjective day at 7-
dpf), and during the night after the day perturbation (N7: night of 7-dpf). There was no significant 
difference in the amount of sleep between perturbed and non-perturbed animals during any of 
these time periods. (I) Normalized sleep rebound following perturbation during the day or night 
for WT animals. Normalized sleep rebound is calculated as the amount of sleep of each perturbed 
animal during the first 4 h of recovery sleep (RS, purple) divided by the average amount of sleep 
of all non-perturbed control animals during this time period. (J-O) Further quantification of 
gefitinib sleep deprivation experiment (Fig. 3D-3G). Quantification of sleep during the night 
before sleep deprivation (N6: 6-dpf), during the 4 h immediately after sleep deprivation (RS: last 
4 h of night at 7-dpf), and during the night after sleep deprivation (N8: night of 8-dpf) in DMSO-
treated (J-L) or gefitinib-treated (M-O) WT zebrafish. Both perturbed gefitinib- and DMSO 
vehicle-treated animals slept more than non-perturbed but identically treated controls during the 
RS period, but not during the nights before or after sleep deprivation. Pooled data from 5 
experiments are shown. n=number of animals. a.u. = arbitrary units. Black, white, and hatched 
bars under behavioral traces indicate night (10 h), day (14 h), and subjective day, respectively. 
***p<0.005 by Mann-Whitney test. 
  
 
  
Figure S6. Inhibition of MAPK/ERK signaling suppresses TGFa 
overexpression-induced sleep
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Fig. S6. Inhibition of MAPK/ERK signaling suppresses TGFa overexpression–induced 
sleep. Tg(hs:tgfa) and their WT siblings were treated with the MEK1/2 antagonists SL327 (A-F) 
or U0126 (G-L), or DMSO vehicle control, immediately after heat shock (yellow bars). Both 
MEK1/2 antagonists suppressed TGFa overexpression-induced effects on locomotor activity 
(A,B,G,H), sleep (D,E,J,K) and sleep bout number (C,I) compared to DMSO-treated siblings. 
Treatment with SL327, but not U0126, blocked the TGFa overexpression-induced effect on sleep 
bout length compared to DMSO-treated controls.  Pooled data from 5 experiments are shown. Bar 
graphs show mean ± SEM. Pre- and Post-HS data is calculated for the day of HS. n=number of 
animals. *p<0.05, **p<0.01, ***p<0.001, n.s. p>0.05 by Two-way ANOVA with Holm–Sidak 
test. 
  
 
Fig. S7. EGFR signaling regulates npvf expression, and TGFa overexpression–induced sleep 
is suppressed in npvf mutant animals. (A,B) Increased npvf mRNA was observed using ISH at 
2 h after heat shock in Tg(hs:tgfa) animals compared to WT siblings. (C,D) Decreased npvf 
mRNA was observed at 45 min after treatment of WT animals with gefitinib compared to DMSO. 
(E-H) No significant difference in NPVF protein level was observed using IHC at 2 h after heat 
shock in Tg(hs:npy) or Tg(hs:hcrt) animals compared to their WT siblings. (I,J) No significant 
difference in Hcrt protein level was observed using IHC at 2 h after heat shock in Tg(hs:tgfa) 
animals compared to WT siblings. Representative images (A,C,E,G,I) and quantification of 
average pixel intensity (B,D,F,H,J) are shown. Graphs show mean ± SEM. Each data point 
represents one animal. *p<0.05, n.s. p>0.05 by Two-way ANOVA with Holm–Sidak test 
(B,F,H,J) or Student’s t-test (D). Scale: 20 m. (K) After heat shock, increased sleep in 
Tg(hs:tgfa) animals was partially suppressed in npvf -/- animals compared to their npvf +/- 
siblings. Pooled data from 3 experiments is shown. n=number of animals. Data shown in the line 
graph is quantified using bar graphs in Fig. 5E. 
  
Figure S7. EGFR signaling regulates npvf expression and TGFa 
overexpression-induced sleep is suppressed in npvf mutant animals
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Figure S8. Association of ERBB4 sleepiness allele with increased ERBB4 expression in 
humans and pharmacological inhibition of KSR2 or ERBB4 decreases sleep in zebrafish
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Fig. S8. Association of ERBB4 sleepiness allele with increased ERBB4 expression in humans 
and pharmacological inhibition of KSR2 or ERBB4 decrease sleep in zebrafish. 
(A)  Significant association is observed between ERBB4 rs7607363 genotypes (G vs A allele) 
with rank normalized gene expression of ERBB4 in human Tibial nerve (n=360 samples; 
normalized effect size of 0.25, p=1.3 x10
-11
, linear regression analysis). (B-I) Pharmacological 
inhibition of ERBB4 by treatment of WT zebrafish with spironolactone resulted in less sleep 
(E,F) and more activity (B,C) during the day compared to DMSO-treated siblings. These changes 
were due to increased waking activity (D) and fewer sleep bouts (G). (J-Q) Pharmacological 
inhibition of KSR2 by treatment of WT zebrafish with APS-2-79 resulted in less daytime and 
nighttime sleep (M,N), shorter nighttime sleep bouts (P), and a trend of increased daytime activity 
(J,K) compared to DMSO-treated siblings.  Pooled data from 10 (B-I) and 8 (J-Q) experiments 
are shown. Bar graphs show mean ± SEM. n=number of animals. *p<0.05, **p<0.01, ***p<0.005  
by Student’s t-test. 
  
Table S1. Variants at ERBB4 and KSR2 associate with self-reported measures of sleep 
quality and quantity in U.K. Biobank subjects. 
 
 
 
Table S2. Descriptive characteristics of U.K. Biobank subjects of European ancestry used 
for sleep trait analysis. 
 
Gene SNP CHR BP
Effect 
Allele
Alt 
Allele EAF INFO Phenotype Beta StdErr P-value
ERBB4 rs7607363 2 213,402,705 G A 0.44 1.00 Sleep Duration, hrs 0.004 0.002 0.095
Daytime Sleepiness, increased frequency 0.006 0.001 8.00x10-9
Hypersomnolence, log odds 0.041 0.052 0.064
Difficulty Waking Up, increased difficulty -0.003 0.002 0.031
Daytime Napping, increased frequency 0.005 0.001 7.50x10-4
Frequent Insomnia Symptoms, log odds 0.000 0.001 0.790
Chronotype, morningness -0.004 0.003 0.071
KSR2 rs1846644 12 117,938,380 C T 0.41 1.00 Sleep Duration, hrs 0.013 0.002 5.30x10-9
Daytime Sleepiness, increased frequency 0.011 0.001 2.50x10-27
Hypersomnolence, log odds 0.074 0.052 8.80x10-4
Difficulty Waking Up, increased difficulty 0.002 0.002 0.140
Daytime Napping, increased frequency 0.018 0.001 2.00x10-41
Frequent Insomnia Symptoms, log odds -0.003 0.001 0.036
Chronotype, morningness 0.003 0.003 0.270
CHR=chromosome, BP=base pair position in hg19, EAF=effect allele frequency, INFO=imputation quality metric, Beta=effect size, StdErr=standard error. n=453,964. Traits and 
P-values in bold indicate genome-wide significant associations (withstand correction for all SNPs tested for that trait).
Results for the following traits were looked up from GWAS summary statistics available at Sleep Disorder Knowledge Portal (http://sleepdisordergenetics.org/): 
Self-report Sleep duration (5), Daytime sleepiness (4); Frequent insomnia symptoms (7) and Chronotype (8).
Table S1. V riants at ERBB4 and KSR2 associate with self-reported measures of 
sleep quality d quantity in UK Biobank subjects
Chronotype Difficulty Waking 
Up
Sleep Duration Frequent Insomnia 
Symptoms
Daytime Napping Excessive Daytime 
Sleepiness
N 451,963 452,724 446,953 237,627 339,400 451,937
Definite morning
=108,083 (24%)
Not at all easy
=17,210 (4%)
≤6 hours
=106,388 (24%)
Never/rarely
=108,357 (46%)
Never/rarely
=203,962 (60%)
Never/rarely
=347,213 (77%)
Somewhat morning
=145,323 (32%)
Not very easy
=61,959 (14%)
7-8 hours
=306,318 (68%)
Usually
=129,270 (54%)
Sometimes
=121,612 (36%)
Sometimes
=92,746 (2%)
Don't know
=46,847 (10%)
Fairly easy
=225,867 (50%)
≥9 hours
=34,247 (8%)
Usually
=13,826 (4%)
Often
=11,950 (3%)
Somewhat evening
=115,629 (26%)
Very Easy
=147,688 (33%)
All of the time
=28 (<1%)
Definite evening
=36,081 (8%)
Sex, male 206,691 (46%) 207,116 (46%) 205,125 (46%) 112,477 (47%) 149,304 (44%) 206,733 (46%)
Age, years 56.77±8.02 56.78±8.03 56.75±8.03 56.68±8.04 56.71±8.04 56.77±8.02
Body Mass Index 
(BMI) 27.4±4.76 27.4±4.76 27.39±4.75 27.56±4.87 26.72±4.21 27.39±4.76
Sleep duration, 
hrs 7.17±1.08 7.17±1.08 7.17±1.08 7.05±1.16 7.20±0.98 7.17±1.08
Mean ± standard deviation or N (%) are shown. 
Table S2. Descriptive characteristics of UK Biobank subjects 
of European ancestry used for sleep trait analysis
